Boston Millennia Partners Adds Healthcare Executive in Residence.Business Editors BOSTON--(BUSINESS WIRE)--Oct. 3, 2001 Boston Millennia Partners is pleased to announce that Robert N. Merold has joined the firm as an Executive in Residence. Bob will support Millennia in sourcing and reviewing quality healthcare and life sciences information technology investment opportunities. Bob brings significant experience in the healthcare and technology sector. Prior to joining Millennia he was COO and a member of the Board of Directors of Proteome, Inc., a leading-edge proteomic data company. Boston Millennia led the initial round of financing for Proteome, which was subsequently acquired by Incyte Genomics, Inc. in December 2000. For the past nine months, Bob has overseen Proteome's integration into Incyte and served as a member of Incyte's information strategy task force. Previously, Bob served for ten years in several executive roles at IMS Health, the world's leading provider of information to the global pharmaceutical community. Among his assignments: launching IMS's flagship database, Xponent, in both the U.S, and Europe; General Manager, Healthcare Division (North America); responsibility for global product direction and strategy; and New Business Development. Before joining IMS (1) See IP Multimedia Subsystem. (2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. , Bob held executive management positions at Bristol-Myers Squibb and Procter & Gamble. "Boston Millennia Partners experience and track record of backing emerging healthcare and life sciences companies clearly positions them as a premier venture firm in this sector," said Merold. "Their guidance was instrumental in helping Proteome become a successful company. I look forward to working again with this great group of professionals and offering my experience to benefit Millennia's portfolio companies." About Boston Millennia Partners Boston Millennia Partners is a private equity investment partnership managing over $700 million in capital. With offices in Boston, Millennia invests in high-growth businesses in the healthcare and life sciences, telecommunications and information technology industries. Typical investments range from $3 to $25 million. The managers at Millennia have funded over 100 companies in the U.S. venture market since 1980. Portfolio companies with whom they have invested include Deltagen (Nasdaq: DGEN DGEN Distributed Generation ), Proteome/Incyte Genomics (Nasdaq: INCY), HotJobs.com (Nasdaq: HOTJ HOTJ House of Taylor Jewelry, Inc ),Yantra Yantra is a Sanskrit word that is derived from the root meaning "to restrain, curb, check".[1][2] Meanings for the noun derived from this root include "that which restrains or fastens, any prop or support", "a fetter", "any instrument or machine", "an , Verio/NTT Communications (NYSE NYSE See: New York Stock Exchange : NTT NTT Nippon Telegraph and Telephone Corporation NTT New Technology Telescope NTT National Technology Transfer, Inc NTT Name That Tune (TV game show) NTT National Tree Trust NTT Number Theoretic Transform ), PAREXEL International (Nasdaq: PRXL), PowerFone/Nextel Communications (Nasdaq: NXTL), Brooks Fiber Properties/MCI WorldCom (Nasdaq: WCOM WCOM MCI/Worldcom (stock symbol) WCOM Windows Component Object Model WCOM Wireless Communication ), and ILEX Ilex a bush bearing berries containing saponins; cause vomiting, diarrhea. Called also holly. Oncology (Nasdaq: ILXO). |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion